MBD-seq cfDNA Methylation Analysis for Early Tumor Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and diagnosing lung, colorectal, and pancreatic cancers at early stages are inadequate, leading to poor patient outcomes due to advanced stage diagnosis.
Innovation Solution
Utilizing methyl-CpG-binding domain sequencing (MBD-seq) to analyze methylation patterns in cell-free DNA (cfDNA) from plasma, serum, or cerebrospinal fluid, focusing on specific CpG islands associated with these cancers, to detect, diagnose, grade, and treat these malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer detection methods are used, then current diagnostic capabilities are maintained, but early detection accuracy and patient outcomes remain inadequate
Solution Approach 1:
The patent segments the cancer detection process by focusing on specific CpG islands (dividing the genome into functional units) and analyzing methylation patterns at these discrete locations. This segmentation enables precise detection of cancer-specific epigenetic changes while reducing complexity compared to whole-genome analysis.
Solution Approach 2:
The patent uses methylated filler DNA as an intermediary substance to enable methylation enrichment. The filler DNA serves as a mediator that allows the MBD-seq method to capture and analyze methylated cfDNA fragments, bridging the gap between sample preparation and detection.
2Measurement precision
If MBD-seq with methylated filler DNA is used, then early cancer detection accuracy is improved, but method complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-methylating filler DNA before use in the MBD-seq protocol. This pre-preparation step ensures that the filler DNA is ready to function as an effective control and enrichment target, simplifying the overall workflow by preparing components in advance rather than during the detection process.
Solution Approach 2:
The patent changes the methylation state parameter of filler DNA to create a controlled reference system. By treating filler DNA with CpG methyltransferase to establish known methylation patterns, the method creates a standardized parameter system that simplifies data interpretation and reduces analytical complexity.
3Measurement precision
If CpG hypermethylation analysis is performed, then cancer severity grading capability is improved, but detection time and processing steps increase
Solution Approach 1:
The patent segments the analysis into specific CpG island regions associated with cancer types, allowing parallel processing of multiple genomic locations. This segmentation enables comprehensive severity assessment across multiple cancer-relevant genes simultaneously, reducing total analysis time compared to sequential examination.
Solution Approach 2:
The patent creates a universal MBD-seq protocol that can detect and grade multiple cancer types (colorectal, lung, pancreatic) simultaneously through a single workflow. The same methylation enrichment and sequencing approach serves multiple diagnostic functions, reducing time loss by avoiding separate specialized assays for each cancer type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Accurately identifies the presence and severity of cancers through CpG hypermethylation patterns, enabling early detection and targeted treatment, thereby improving patient outcomes.
Implementation Method 1
methyl-CpG-binding domain sequencing (MBD-seq) to detect, type, grade, and/or treat a cancer
Implementation Method 2
generating methylated filler DNA
Data Source
AI summary
Disclosed are methods of using cell-free DNA (cfDNA) methylation for the detection, typing, and grading of cancer.